Nauman Chaudary, MD
Pulmonary Disease · Richmond, VANPI 1811976582
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,468 of the $13,470 with a category attached, or 92.6%. Insmed, Inc. accounts for 68.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $9,349 and has fallen 73.5% since, to $2,479 in 2025.
Across 16 payments — averaging $841.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$9K
- Baxter Healthcare$2K
- PARI Respiratory Equipment, Inc.$2K
- Grifols Shared Services North America, Inc.$97
- Alcresta Therapeutics, Inc.$28
- Vertex$18
- plus $32 from 2 others
Across 46 payments — averaging $1377.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$59K
- Boehringer Ingelheim International GmbH$4K
What the payments were for
- Consulting fees$12,46893%
- Travel & lodging$5354%
- Food & beverage$4673%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 5 | $9,258 |
| Baxter Healthcare | 4 | $2,409 |
| PARI Respiratory Equipment, Inc. | 2 | $1,628 |
| Grifols Shared Services North America, Inc. | 1 | $97 |
| Alcresta Therapeutics, Inc. | 1 | $28 |
| Vertex | 1 | $18 |
| Electromed, Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,470 in reported general payments places this provider in the 80th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 137 | $3,603,648 |
| CreonLipase/Protease/Amylase | 37 | $227,957 |
| CaystonAztreonam Lysine | 17 | $196,992 |
| ZenpepLipase/Protease/Amylase | 30 | $102,220 |
| PertzyeLipase/Protease/Amylase | 19 | $69,900 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $21,040 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $16,753 |
| Spiriva HandihalerTiotropium Bromide | 19 | $9,405 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $7,365 |
| Tiotropium Bromide | 18 | $6,833 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $4,932 |
| DuleraMometasone/Formoterol | 14 | $4,399 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $903 |
| Azithromycin | 87 | $837 |
| Mometasone Furoate | 14 | $812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $18 | $3,603,648137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Richmond
- Sujoy GillRichmond$296K
- Patricia SimeRichmond$113K
- Shilpa JohriRichmond$37K
- Apostolos PerelasRichmond$31K
- John SentzRichmond$20K
- Glenn GiesselRichmond$14K
- Michael MistrettaRichmond$13K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.